Adults over 60 are increasingly seeking out the shingles vaccine to protect against cognitive decline, even though the vaccine is not officially approved for preventing dementia. British high street chemists report a notable rise in demand for the jab, driven largely by individuals hoping to stave off memory loss. While the National Health Service provides the vaccine for free to specific age groups, younger adults under 65 frequently pay approximately £450 for the full two-dose course out of pocket, according to reports by The Guardian.
This growing consumer trend follows a flurry of observational studies suggesting a potential link between receiving the shingles vaccination and a lower risk of developing dementia. In the brain, the varicella zoster virus can drive inflammation, nerve cell stress, and the accumulation of amyloid and tau proteins. Pascal Geldsetzer, an epidemiologist involved in research at Stanford University, notes that compelling data from natural experiments—such as a vaccination rollout in Wales utilizing the older live-attenuated vaccine Zostavax—indicate measurable reductions in neurological risk. Similar effects have since been reported in follow-up investigations across Australia and Ontario, Canada.
Scientific Uncertainty Separates Observational Data from Clinical Proof
Despite encouraging epidemiological numbers, researchers caution that observational studies do not definitively prove the vaccine actively prevents dementia. Pascal Geldsetzer points out that hospital administrative data may fall short for tracking dementia because general practitioners manage the vast majority of patients. Furthermore, some datasets fail to show consistent protective effects, raising questions about whether older live vaccines function differently than newer formulations or if data quirks skew the results.
To resolve these uncertainties, two major randomized clinical trials are currently underway in Finland and Denmark to test whether the newer Shingrix vaccine genuinely protects against dementia. However, those formal clinical trials will not report final results for years. Until definitive data emerges from these trials, health authorities maintain that vaccine recommendations remain strictly a matter for government advisory bodies, though researchers like Geldsetzer do not discourage individuals from seeking the shot for personal prevention.
Frequently Asked Questions About Vaccines and Dementia Risk
How much does the shingles vaccine cost for adults under 65 in the UK?
Most adults under 65 pay around £450 for the full two-dose course at high street chemists when they do not qualify for free coverage under the National Health Service.
Which specific shingles vaccine was studied in the influential Stanford University research?
The Stanford University research focused on Zostavax, which was a live-attenuated vaccine containing a weakened version of the varicella zoster virus used during a vaccination program in Wales.
When will the ongoing clinical trials in Finland and Denmark finish?
Major clinical trials currently underway in Finland and Denmark to determine if Shingrix genuinely protects against dementia will not report their final results for years.
Related reading